Probiotics in the Reduction of Adverse Effects and Dysbiosis of H. Pylori Eradication

• Status: Unknown status
• Trial end date: 2020-07-31
• Target enrollment: 0
• Participant gender: All

Summary

The investigators aimed to assess the effect of probiotic supplementation with Vigiis 101-LAB during H. pylori eradication therapy with 14-day sequential therapy in the reduction of adverse effects and the restoration of the dysbiosis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital

Criteria

Inclusion Criteria:

• Adult patients aged greater than 20 years with H. pylori infection naïve to treatment are considered eligible for enrollment.

Exclusion Criteria:

• children and teenagers aged less than 20 years

• history of gastrectomy

• gastric malignancy, including adenocarcinoma and lymphoma

• previous allergic reaction to antibiotics (amoxicillin, metronidazole, clarithromycin, probiotics) and PPI (esomeprazole)

• contraindication to treatment drugs

• pregnant or lactating women

• severe concurrent disease

• concomitant use of clopidogrel

• unwilling to accept random assignment of subjects